Weiss Ratings Reaffirms "Sell (D-)" Rating for Agenus (NASDAQ:AGEN)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Agenus (NASDAQ: AGEN), indicating ongoing concerns regarding the company's performance.
• Agenus recently reported a loss of ($1.00) EPS for its quarterly earnings, missing expectations and generating revenue significantly below estimates at $25.70 million.
• The stock has a current price of $4.15, with a consensus price target of $14.50 from various analysts, reflecting mixed recommendations on the stock.

Agenus (NASDAQ:AGEN - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

AGEN has been the subject of a number of other reports. Wall Street Zen cut shares of Agenus from a "buy" rating to a "hold" rating in a research note on Sunday, August 17th. Zacks Research raised shares of Agenus to a "hold" rating in a research note on Tuesday, August 12th. Finally, HC Wainwright reissued a "buy" rating and set a $23.00 price objective on shares of Agenus in a research note on Wednesday, September 10th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $14.50.

Agenus Price Performance

Shares of AGEN stock traded down $0.10 during midday trading on Wednesday, reaching $4.15. 211,548 shares of the company traded hands, compared to its average volume of 758,067. The firm's 50 day simple moving average is $4.51 and its two-hundred day simple moving average is $4.09. Agenus has a 1-year low of $1.38 and a 1-year high of $7.34. The firm has a market cap of $132.22 million, a PE ratio of -0.58 and a beta of 1.43.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million. As a group, research analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Institutional investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC lifted its holdings in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after buying an additional 5,000 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new position in Agenus in the 2nd quarter worth about $50,000. Jump Financial LLC bought a new position in shares of Agenus in the second quarter valued at approximately $55,000. Acadian Asset Management LLC bought a new position in shares of Agenus in the first quarter valued at approximately $58,000. Finally, Savant Capital LLC bought a new stake in Agenus during the second quarter worth approximately $73,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.